Version 5

Cobolimab

Medicine

Extended indication Cobolimab in combination with dostarlimab and docetaxel for second line, third line treatment of advanced or metastatic EGFR-negative, ALK-negative, o
Therapeutic value No estimate possible yet
Registration phase Clinical trials

Product

Active substance Cobolimab
Domain Oncology
Reason of inclusion New medicine (specialité)
Main indication Lung cancer
Extended indication Cobolimab in combination with dostarlimab and docetaxel for second line, third line treatment of advanced or metastatic EGFR-negative, ALK-negative, or ROS-1-negative Non-small cell lung cancer in adults and elderly who have progressed on prior anti-PD-(L)1 therapy and chemotherapy.
Manufacturer GSK
Route of administration Unknown
Therapeutical formulation Unknown
Budgetting framework Intermural (MSZ)
Additional remarks Cobolimab is een monoklonaal antilichaam tegen de remmende T-celreceptor, T-celimmunoglobuline en mucinedomein-3 (TIM-3), met potentiële immuun checkpoint remmende en antineoplastische activiteiten.

Registration

Registration route Centralised (EMA)
ATMP No
Submission date 2026
Expected Registration 2027
Orphan drug No
Registration phase Clinical trials

Therapeutic value

Therapeutic value No estimate possible yet

This assessment does not indicate any potential inclusion in the package.
Substantiation De resultaten moeten nog worden afgewacht. De verwachting is dat het mogelijk wel wat kan gaan betekenen omdat docetaxel niet erg effectief is.
References NCT04655976 (COSTAR Lung)

Expected patient volume per year

Patient volume < 3,700

Market share is generally not included unless otherwise stated.
References NKR2021
Additional remarks In 2021 waren er 10.096 diagnoses NSCLC in Nederland. Dit betrof 1.727 patiënten in stadium 1, 822 patiënten in stadium 2, 2.231 patiënten in stadium 3, 5.247 patiënten in stadium 4. Ongeveer 50% van de stadium 3 en stadium 4 patiënten gaat door voor een tweedelijn therapie. Het zal ongeveer gaan om 3.700 patiënten.

Expected cost per patient per year

Potential total cost per year

Additional remarks Er is nog niets bekend over de mogelijke prijs.

Off label use

Indication extension

Other information